



For immediate release

Seinäjäki, Finland 4.02.2025

Eevia Health divests eye-health lead candidate intellectual property

Eevia Health Plc ("Eevia" or "The Company") has agreed to sell intellectual property related to its lead eye-health compound to Havu Health Oy for KEUR 800. The compound, named Retinari™, is promising in fighting Age-related Macular Degeneration, the primary cause of blindness.

Retinari™ is a stilbene extract that has shown strong pre-clinical results in preventing the onset and progression of Age-related Macular Degeneration (AMD), the leading cause of blindness in the U.S and among the elderly in Europe the past six years. Eevia has developed this pine wood-derived compound, standardized for a specific polyphenolic molecule within the stilbene class. Eevia has produced multiple test batches of the product in Eevia's green chemistry facility in Finland and the raw material is an upcycled wood side stream.

The lead compound, trade-named Retinari™, has undergone extensive testing, including biomarker studies, mice trials, RPE (Retina Pigment Epithelial) cell studies, and a human primary cell study. Results suggest Retinari™ improves the underlying conditions of AMD by enhancing autophagy and cytoprotective capacity. The product may potentially help millions of people avoid blindness.

Retinari™ received top scores in fiercely competitive international funding competitions, twice reaching the pitching finals for the European Innovation Council Accelerator program (Horizon 2020), ranking in the top 2% of over 12,000 applicants. However, due to its early-stage development, Eevia did not secure EIC funding but was awarded the Seal of Excellence (See attached Seal). Subsequent national funding applications for a safety study to Business Finland were also rejected, despite strong interest from leading global eye-health brands. Without funding for necessary safety studies, the project held no viable path forward before humans may consume the product for testing and is without value for Eevia.

The inventors, including Eevia's CTO Petri Lackman, requested rights to commercialize the product outside Eevia. To preserve the project's value potential, Eevia agreed with Havu Health Oy, a startup founded by Lackman, to sell certain intellectual property rights for KEUR 800. The book value as an intangible asset has been written down over the years and stood at 31.12.24 at c. KEUR 123. Hence, the sale creates an additional value of KEUR 677, and Eevia will retract the application to Business Finland to convert the loan to a grant.

The sale of the intellectual property is extensively documented and is subject to third party fair value assessment and consent by creditors and respective Boards. Havu Health Oy intends to commercialize the product and is applying for development funding and in contact with corporate venture funds to fund the development. Eevia Health will receive shares in Havu Health Oy as payment for the sold intellectual assets.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com

Telephone: +358 400 22 5967

This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication through the contact person's agency on February 4, 2025, at 16:25 EST.



INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) [EEVIA](#).

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.